Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

4. Stock Option Plan (Tables)

4. Stock Option Plan (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

				Options Outstanding
	Options Available			Number ofOptions			Weighted-Average Exercise Price
Balances at January 1, 2017		420,000			280,000		$	0.001
Option pool increase(1)		900,000
Granted(2)		(378,592	)		378,592			1.63
Forfeited		—			—			—
Exercised		—			—			—
Balances at December 31, 2017		941,408			658,592			0.94
Granted(3)		(37,004	)		37,004			6.00
Forfeited(4)		34,167			(34,167	)		6.00
Exercised		—			—			—
Balances at June 30, 2018		938,571			661,429		$	0.96

(1)	In October 2017, the Company’s Board of Directors increased the option pool to 1,600,000 shares.

(2)

336,544 options vest 6/48ths at the six-month anniversary of grant date and 1/48th per month thereafter; 21,024 options vest 6/24ths on the six-month anniversary of grant date and 1/24th per month thereafter; and 21,024 options vest 6/42nds on the six-month anniversary of grant date and 1/42nd per month thereafter.

(3)	32,004 options vest as follows: options to purchase up to 12,000 shares of common stock vest on the grant date, options to purchase up to 1,667 shares of common stock vest on the 1st of each month thereafter. 5,000 options vest 6/48ths on the grant date and 1/48th per month thereafter.

(4)	Options forfeited as a result of an employee termination.

Summary of options outstanding

Exercise Prices			Number of Shares subject to Options Outstanding		Weighted Average Remaining Contractual Term	Number of Shares Subject to Options Fully Vested and Exercisable		Weighted Average Remaining Contractual Term
$	0.001			555,520	8.2 years		371,840	8.0 years
$	6.00			105,909	9.3 years		43,228	9.4 years
		661,429			415,068